Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Ultragenyx Pharmaceutical Inc. (RARE) has a Wall Street consensus price target of $48.78, based on estimates from 33 covering analysts. With the stock currently trading at $23.39, this represents a potential upside of +108.6%. The company has a market capitalization of $2.26B.
Analyst price targets range from a low of $34.00 to a high of $63.00, representing a 59% spread in expectations. The median target of $50.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 27 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, RARE trades at a trailing P/E of -3.7x. Analysts expect EPS to grow +27.1% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how RARE stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for RARE is $48.78, representing 108.6% upside from the current price of $23.39. With 33 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
RARE has a consensus rating of "Buy" based on 33 Wall Street analysts. The rating breakdown is predominantly bullish, with 27 Buy/Strong Buy ratings. The consensus 12-month price target of $48.78 implies 108.6% upside from current levels.
RARE's current price is $23.39 with a consensus target of $48.78 (108.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $63 for RARE, while the most conservative target is $34. The consensus of $48.78 represents the median expectation. These targets typically reflect 12-month expectations.
RARE is heavily covered by Wall Street, with 33 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 27 have Buy ratings, 5 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RARE stock forecast based on 33 Wall Street analysts shows a consensus price target of $48.78, with estimates ranging from $34 (bear case) to $63 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on RARE, with a "Buy" consensus rating and $48.78 price target (108.6% upside). 27 of 33 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RARE analyst price targets range from $34 to $63, a 59% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $48.78 consensus represents the middle ground.